DR. RICHARD LEE WATSON, MD
Marriage and Family Therapists at Cougar Trl, Mcpherson, KS

2012012, May 17, 2012

Apr 29, 2011

13/097565

Richard L. Watson - McPherson KS, US
Anthony B. Wood - Dallas TX, US
Gregory J. Archambeau - Puyallup WA, US

Revalesio Corporation - Tacoma WA

A61K 33/00, A61K 31/785, A61K 38/21, A61P 29/00, A61P 25/28, A61P 25/16, A61P 39/00, A61K 9/00, A61K 39/395, B82Y 5/00

424400, 424613, 424 7837, 424 856, 4241331, 4241721, 977915

Provided are methods for protecting against or reducing neurotoxicity of exposure to a neurotoxic agent, comprising administering an electrokinetically altered aqueous fluid as provided herein in an amount sufficient to provide for neuroprotection against the neurotoxic agent, preferably where protecting against or reducing loss of motor coordination in the subject exposed to the neurotoxin is afforded. In certain aspects, protecting or reducing neurotoxin-mediated neuronal apoptosis is afforded, and/or activating or inducing at least one of PI-3 kinase and Akt phosphorylation in neurons is afforded. Preferably, administering the fluid comprises administering the fluid prior to exposure to the neurotoxic agent. Additionally provided are methods for preserving or improving motor coordination in a subject having a neurodegenerative condition or disease, comprising administering an electrokinetically altered aqueous fluid as provided herein in an amount sufficient to provide for preserving or improving motor coordination in the subject.

2004021, Oct 28, 2004

May 24, 2004

10/852021

Richard Watson - McPherson KS, US
Ronald Hicks - San Antonio TX, US
Carrie Bader - Austin TX, US
Philip Leung - Austin TX, US

A61D001/10

606/120000

A novel umbilical cord clamp and a combined umbilical cord clamp and cutter are provided for clamping and cutting umbilical cords in one motion. The cutter comprises two shells joined by a longitudinal hinge. A transverse blade is mounted in one shell, and a cutting support is mounted in the other shell across from the blade. A clamping member is provided on one side of the blade as part of the cutter, and a removable clamp is provided on the other side of the blade. The umbilical cord to be cut is oriented generally parallel to the hinge and lying across the cutting support. As the shells of the cutter are closed, the umbilical cord is clamped on both sides of the blade, and the blade severs the umbilical cord in the same motion. After the cut is completed, the removable clamp is removed from the cutter, preferably revealing an aesthetically pleasing form such as the face of a koala bear.

2012026, Oct 18, 2012

Apr 13, 2012

13/446844

Richard L. WATSON - McPherson KS, US

Revalesio Corporation - Tacoma WA

A61K 33/00, A61K 38/21, A61K 39/395, A61K 35/12, A61K 33/30, A61P 25/16, A61P 25/14, A61P 25/06, A61P 25/00, C12N 5/0783, A61K 9/08, A61P 25/28, B82Y 5/00

424400, 424613, 424 856, 4241581, 424 9371, 424615, 424614, 435375, 977700, 977915

Provided are methods for treating inflammatory neurodegenerative diseases (e.g., multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, stroke/cerebral ischemia, head trauma, spinal cord injury, Huntington's disease, migraine, cerebral amyloid angiopathy, inflammatory neurodegenerative condition associated with AIDS, age-related cognitive decline; mild cognitive impairment and prion diseases in a mammal), or at least one symptom thereof in a subject by administering a therapeutic composition comprising at least one electrokinetically-altered fluids (e.g., electrokinetically-generated oxygen-enriched fluids) of the present invention. Particular aspects provide methods for inhibiting and/or modulating the function and/or activity of effector T-cells, and/or for cell-based tolerogenic therapy (e.g., by modulating development and/or function and/or activity of Tcells and/or dendritic cells (DCs) and/or T17 cells (e.g., RORγt T17 cells). In certain aspects such methods comprise ex vivo exposure of T-cells and/or APC (e.g., dendridic cells) to at least one electrokinetically-altered fluid as disclosed herein. Combination therapies are additionally provided.

2009027, Nov 5, 2009

Oct 27, 2008

12/259101

Richard L. Watson - McPherson KS, US
Anthony B. Wood - Dallas TX, US
Gregory J. Archambeau - Puyallap WA, US

Revalesio Corporation - Tacoma WA

A61K 33/00, A61P 11/00

424600

Provided are compositions and methods for treating or preventing lung or respiratory disorders or conditions characterized by airflow obstruction or limitation, or a symptom thereof (e.g., asthma, rhinitis, allergic rhinitis (e.g. nose respiratory tract), and chronic obstructive pulmonary disease (COPD) and COPD-associated conditions (e.g., bronchitis, emphysema, asthma), emphysema, pneumonia, bronchitis, influenza, SARS, tuberculosis, and whooping cough (pertussis), and the like) in a subject in need thereof by administering a therapeutic composition comprising at least one electrokinetically generated fluid (including gas-enriched electrokinetically generated fluids) as disclosed herein, the electrokinetically altered aqueous fluid suitable to alter cellular membrane structure or function sufficient to provide for modulation of intracellular signal transduction, wherein treating a lung disorder or a symptom thereof is thereby afforded. Additional aspects relate to therapeutic compositions, and combination treatment methods comprising administration of at least one electrokinetically generated fluid in combination with at least one additional therapeutic agent.

2010002, Feb 4, 2010

May 4, 2009

12/435262

Richard L. Watson - McPherson KS, US
Anthony B. Wood - Dallas TX, US
Gregory J. Archambeau - Puyallap WA, US

Revalesio Corporation - Tacoma WA

C12N 5/00, A61K 31/22, A61P 11/00

514546, 435375

Provided are electrokinetically-altered fluids (e.g., gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide, upon contact with a cell, modulation of at least one of cellular membrane potential and cellular membrane conductivity. Particular aspects of the present invention provide compositions and methods suitable for modulation of at least one of cellular membrane potential and cellular membrane conductivity. Additional aspects provide compositions and methods suitable for modulating intracellular signal transduction, including modulation of at least one of membrane structure, membrane potential or membrane conductivity, membrane proteins or receptors, ion channels, and calcium dependant cellular messaging systems, comprising use of the inventive electrokinetically altered solutions to impart electrochemical and/or conformational changes in membranous structures (e.g., membrane proteins, receptors and/or other components) including G-protein coupled receptors (GPCRs), G-proteins, and/or intracellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes).

2010031, Dec 9, 2010

Apr 27, 2010

12/768615

Richard L. Watson - McPherson KS, US
Anthony B. Wood - Dallas TX, US
Gregory J. Archambeau - Puyallup WA, US

Revalesio Corporation - Tacoma WA

A61K 31/58, A61K 9/14, A61K 31/138, A61P 3/10, A61P 29/00

424489, 514653, 514171

Provided are electrokinetically-altered fluids (gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating diabetes and diabetes-associated conditions or disorders (e.g., insulin resistance), or symptoms thereof. Provided are electrokinetically-altered ioinic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said inflammatory responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-altered fluids (e.g., electrokinetically-altered gas-enriched fluids and solutions) and therapeutic compositions.

2001003, Oct 18, 2001

Jan 10, 2001

09/758627

Richard Watson - McPherson KS, US

A61B007/02

181/131000, 381/067000

A electronic stethoscope head is combined with a standard stethoscope air tube headset assembly to provide a personally portable ECG stethoscope system for auscultating a living body. The electronic stethoscope head comprises a stethoscope body having a chest-bell, an air tube connector (or connectors), and a display module mounted to it. The chest-bell has a rim for contacting the body, and a base adapted to attach to the stethoscope body. An electrode assembly having at least two electrodes is disposed on the rim of the chest-bell to contact the body during auscultation and receive electrical signals from the body. The electrical signals are conducted to the display module. The display module is mounted on the stethoscope body, and receives and processes the electrical signals and display a representation of the electrical signals on a view screen, like an LCD display screen. An air passage is disposed within the stethoscope body to provide air pressure communication between the chest-bell and the air tube connector(s). The air tube connector(s) provide for attaching the electronic stethoscope head to a standard stethoscope air tube headset assembly.

RE42834, Oct 11, 2011

Oct 16, 2009

12/580991

Richard Watson - McPherson KS, US

KCI Licensing Inc. - San Antonio TX

A61M 1/00

604319

The vacuum desiccator low pressure vacuum pump and trap and is transportable upon a user's person. The device is especially useful to remove excess fluids from wounds and incisions as they heal. The device includes a desiccator cartridge containing a fluid trapping agent. The desiccator cartridge is connected to a vacuum pump member providing a low vacuum pressure to the interior chamber of the desiccator cartridge. A small battery powered, electric motor drives the pump member. An electrical control circuit, including the battery power source, controls the operation of the electric motor. A single passage, one-way, gas/liquid flow pathway connects the inlet port of the desiccator cartridge to an occlusive dressing covering the wound to be drained. The control circuit includes one or more ancillary circuits for controlling operation of the device, such as: a power circuit, a moisture sensor, a timer circuit, a vacuum pressure sensor, and a pressure differential sensor.

8445546, May 21, 2013

May 4, 2010

12/773825

Anthony B. Wood - Dallas TX, US
Richard L. Watson - McPherson KS, US
Gregory J. Archambeau - Puyallup WA, US

Revalesio Corporation - Tacoma WA

B01F 3/04

516 10

Provided are electrokinetically-altered fluids (e. g. , gas-enriched (e. g. , oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized gas-containing nanostructures in an amount sufficient to provide, upon contact with a cell, modulation of at least one of cellular membrane potential and cellular membrane conductivity. Further provided are the methods of making the electrokinetically-altered ionic aqueous fluid compositions. Particular aspects provide for regulating or modulating intracellular signal transduction associated by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e. g. , tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular methods of producing the electrokinetically-altered fluids.

2013029, Nov 7, 2013

Mar 27, 2013

13/851888

Gregory J. Archambeau - Puyallup WA, US
Richard L. Watson - McPherson KS, US

A61J 3/00, A61K 33/00, A61K 9/10

424400, 424613

Provided are electrokinetically-altered fluids (e.g., gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide, upon contact with a cell, modulation of at least one of cellular membrane potential and cellular membrane conductivity. Further provided are the methods of making the electrokinetically-altered ionic aqueous fluid compositions. Particular aspects provide for regulating or modulating intracellular signal transduction associated by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular methods of producing the electrokinetically-altered fluids. The electrokinetically-altered fluid compositions and methods of producing the fluid include electrokinetically-altered ionic aqueous fluids optionally in the form of solvated electrons stabilized with molecular oxygen.